{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T04:40:40Z","timestamp":1699677640686},"reference-count":19,"publisher":"Medical Association of Nippon Medical School","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2023,10,25]]},"DOI":"10.1272\/jnms.jnms.2023_90-508","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T22:14:48Z","timestamp":1685657688000},"page":"381-386","source":"Crossref","is-referenced-by-count":0,"title":["Y-site Injection Physical Compatibility of Remdesivir with Select Intravenous Drugs Used in Palliative Care and for Treating Coronavirus Disease 2019"],"prefix":"10.1272","volume":"90","author":[{"given":"Masayoshi","family":"Kondo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Gempei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Tagui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouhei","family":"Fukao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","unstructured":"1. Veklury (Remdesivir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2020."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yamakawa K, Yamamoto R, Terayama T, et al. Japanese rapid\/living recommendations on drug management for COVID-19: updated guidelines (July 2022). Acute Med Surg. 2022 Oct;9 (1):e789.","DOI":"10.1002\/ams2.789"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Takahashi Y, Wakita H, Ishihara T, et al. Short-course remdesivir for healthcare-associated COVID-19: case series from a non-acute care hospital. J Infect Chemother. 2023 Jan;29 (1):95-7.","DOI":"10.1016\/j.jiac.2022.08.025"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Panagopoulos P, Petrakis V, Trypsianis G, Papazoglou D. Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story. J Chemother. 2022 Dec;34 (8):550-3.","DOI":"10.1080\/1120009X.2022.2099693"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012 Feb;13 (2):e58-68.","DOI":"10.1016\/S1470-2045(12)70040-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pilia E, Belletti A, Fresilli S, Finco G, Landoni G. Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. J Thromb Thrombolysis. 2022;54 (3):420-30.","DOI":"10.1007\/s11239-022-02681-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Brown A, Westley K, Robson J, et al. Furosemide in end-stage heart failure: community subcutaneous infusions. BMJ Support Palliat Care. 2022 Dec;12 (e6):e763-6.","DOI":"10.1136\/bmjspcare-2019-002158"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hisanaga T, Shinjo T, Morita T, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol. 2010 Aug;40 (8):739-45.","DOI":"10.1093\/jjco\/hyq048"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Parsons HA, Shukkoor A, Quan H, et al. Intermittent subcutaneous opioids for the management of cancer pain. J Palliat Med. 2008 Dec;11 (10):1319-24.","DOI":"10.1089\/jpm.2008.0155"},{"key":"10","unstructured":"10. Solyugen F. Injection [package insert]. Tokyo: Hikari Pharmaceutical Co., Ltd.; 2022. Japanese."},{"key":"11","unstructured":"11. Bfluid Injection [package insert]. Tokushima: Otsuka Pharmaceutical Factory, Inc.; 2022. Japanese."},{"key":"12","unstructured":"12. Elneopa-NF No.2 Injection [package insert]. Tokyo: Otsuka Pharmaceutical Factory, Inc.; 2022. Japanese."},{"key":"13","unstructured":"13. Ministry of Health, Labour and Welfare. The Japanese Pharmacopeia, Eighteenth Edition [Internet]. Tokyo: Ministry of Health, Labour and Welfare; 2021. [cited 2023 Apr 21]. Available from: https:\/\/www.pmda.go.jp\/rs-std-jp\/standards-development\/jp\/0192.html"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kondo M, Nagano M, Yoshida M, et al. Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019. J Nippon Med Sch. 2021 Dec 29;88 (6):533-9. Epub 2021 Mar 9.","DOI":"10.1272\/jnms.JNMS.2022_89-104"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ghazi IM Dr, El Nekidy WS Dr, Sood AMr, et al. Y-site Administration of Imipenem\/Cilastatin\/Relebactam With Common Intravenous Medications. Clin Ther. 2020 Mar;42 (3):475-85. Epub 2020 Mar 2.","DOI":"10.1016\/j.clinthera.2020.01.017"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Housman ST, Tessier PR, Nicolau DP, Kuti JL. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm. 2011 Dec 1;68 (23):2265-70.","DOI":"10.2146\/ajhp100663"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kondo M, Yoshida N, Yoshida M, et al. Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health Syst Pharm. 2023 Jan 1;80 (1):e53-8.","DOI":"10.1093\/ajhp\/zxac262"},{"key":"18","unstructured":"18. Octreotide for s.c. injection [package insert]. Tokyo: Aska Pharmaceutical Co., Ltd.; 2021. Japanese."},{"key":"19","unstructured":"19. Furosemide Injection 20 mg &quot;TOWA&quot; [Pharmaceutical interview form]. Osaka: Towa Pharmaceutical Co., Ltd.; 2019. Japanese."}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/5\/90_JNMS.2023_90-508\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T04:04:40Z","timestamp":1699675480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/90\/5\/90_JNMS.2023_90-508\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2023_90-508","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"article-number":"JNMS.2023_90-508"}}